MedTrace Logo

Combined Advanced Targeted Therapy for Inflammatory Bowel Disease

NCT07660289 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 117

Last updated 2026-06-24

No results posted yet for this study

Summary

The aim of this retrospective and prospective observational study is to investigate and compare the real-world effectiveness and safety of different dual-target combination therapies in patients with inflammatory bowel disease (IBD).

The key questions to be addressed are:

In patients with refractory IBD who receive either two biologic agents or one biologic agent plus one small molecule drug, what is the real-world effectiveness and safety of different combination regimens?

The researchers will conduct a retrospective analysis of medical records and electronic health data from patients diagnosed with IBD, and will enroll and document patients receiving combination advanced targeted therapy (CATT) for long-term follow-up. The treatments received by these patients are part of routine first-line clinical care or routine rescue clinical care. All treatment decisions were made by treating clinicians according to the standard of care; the investigator did not assign or modify any therapeutic interventions. Data will be collected during a defined follow-up period to compare the real-world effectiveness and safety profiles of different treatment exposure strategies.

Conditions

  • IBD (Inflammatory Bowel Disease)
  • Combined Advanced Targeted Therapy
  • Combination Therapy

Interventions

DRUG

Combination therapy

Combination therapy in this study is defined as the concurrent use of either two biologic agents, or one biologic agent together with one small molecule agent.

Sponsors & Collaborators

  • Xijing Hospital of Digestive Diseases

    lead OTHER

Eligibility

Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-20
Primary Completion
2026-05-10
Completion
2026-06-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07660289 on ClinicalTrials.gov